All eyes are on new and forthcoming drugs as Bristol-Myers Squibb ($BMY) reports a 12% increase in first-quarter profits, fueled by rising sales of cancer drugs Yervoy and Sprycel and hepatitis B treatment Baraclude. Report
All eyes are on new and forthcoming drugs as Bristol-Myers Squibb ($BMY) reports a 12% increase in first-quarter profits, fueled by rising sales of cancer drugs Yervoy and Sprycel and hepatitis B treatment Baraclude. Report